One of China’s leading generic pharmaceutical companies has purchased the rights to commercialise an experimental drug developed by the Chinese military for treating Ebola, though medical experts said the drug is still at an early stage of development.
Sichuan Pharmaceutical, which is part owned by Morgan Stanley private equity funds, is one of the top sellers of prescription drugs to hospitals in China.
In an announcement late on Wednesday, Sihuan said it had paid a Rmb10m technology transfer and drug development fee to the Chinese Academy of Military Medical Sciences, which developed the anti-Ebola drug jk-05, and will work with the academy to develop it.
您已閱讀16%（663字），剩余84%（3489字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。